Michelle Gilson
Stock Analyst at Morgan Stanley
(1.12)
# 3,605
Out of 4,876 analysts
31
Total ratings
32.14%
Success rate
-7.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michelle Gilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Upgrades: Overweight | $10 → $20 | $5.17 | +286.85% | 4 | Jan 9, 2025 | |
| CORT Corcept Therapeutics | Initiates: Buy | $30 | $73.22 | -59.03% | 1 | Feb 2, 2022 | |
| RZLT Rezolute | Maintains: Buy | $30 → $17 | $4.35 | +290.80% | 2 | Nov 29, 2021 | |
| ASND Ascendis Pharma | Maintains: Buy | $190 → $196 | $172.14 | +13.86% | 5 | Jun 1, 2021 | |
| TVTX Travere Therapeutics | Maintains: Buy | $48 → $45 | $14.77 | +204.67% | 3 | May 27, 2021 | |
| STOK Stoke Therapeutics | Maintains: Buy | $72 → $76 | $11.63 | +553.76% | 4 | Mar 11, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $95 → $91 | $55.17 | +64.94% | 12 | Mar 1, 2021 |
Vir Biotechnology
Jan 9, 2025
Upgrades: Overweight
Price Target: $10 → $20
Current: $5.17
Upside: +286.85%
Corcept Therapeutics
Feb 2, 2022
Initiates: Buy
Price Target: $30
Current: $73.22
Upside: -59.03%
Rezolute
Nov 29, 2021
Maintains: Buy
Price Target: $30 → $17
Current: $4.35
Upside: +290.80%
Ascendis Pharma
Jun 1, 2021
Maintains: Buy
Price Target: $190 → $196
Current: $172.14
Upside: +13.86%
Travere Therapeutics
May 27, 2021
Maintains: Buy
Price Target: $48 → $45
Current: $14.77
Upside: +204.67%
Stoke Therapeutics
Mar 11, 2021
Maintains: Buy
Price Target: $72 → $76
Current: $11.63
Upside: +553.76%
BioMarin Pharmaceutical
Mar 1, 2021
Maintains: Buy
Price Target: $95 → $91
Current: $55.17
Upside: +64.94%